证券代码：688607 证券简称：康众医疗 江苏康众数字医疗科技股份有限公司 2024 年限制性股票激励计划 （草案修订稿） 江苏康众数字医疗科技股份有限公司 二〇二五年四月 江苏康众数字医疗科技股份有限公司 2024 年限制性股票激励计划（草案修订稿） 声 明 公司及全体董事、监事保证本激励计划内容不存在虚假记载、误导性陈述或 者重大遗漏，对本激励计划内容的真实性、准确性、完整性承担个别和连带的法 律责任。 所有激励对象承诺，因公司相关信息披露文件中有虚假记载、误导性陈述或 者重大遗漏，导致不符合权益授予安排或者归属安排的，激励对象应当自公司相 关信息披露文件被确认存在虚假记载、误导性陈述或者重大遗漏后，将参与本激 励计划所获得的全部利益返还公司。 1 江苏康众数字医疗科技股份有限公司 2024 年限制性股票激励计划（草案修订稿） 特别提示 一、本激励计划依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股权激励管理办法》《上海证券交易所科创板股票上市规则》《科创 板上市公司自律监管指南第 4 号—股权激励信息披露》《江苏康众数字医疗科技 股份有限公司章程》等有关规定而制订。 二、本激励计划的 ...

江苏康众数字医疗科技股份有限公司 2024 年限制性股票激励计划考核管理办法（修订稿） 江苏康众数字医疗科技股份有限公司（以下简称"公司"）为完善内部长效 激励与约束机制，吸引和留住优秀人才，充分调动核心人员的工作积极性和创造 性，实现持续、健康发展，按照收益与贡献对等的原则，推出 2024 年限制性股 票激励计划（以下简称"本激励计划"）。 本办法适用于本激励计划确定的激励对象，包括公司董事、高级管理人员以 及公司（含子公司）其他核心员工，不包括公司独立董事和监事。 四、考核机构 考核评价工作由公司董事会薪酬与考核委员会负责领导、组织，公司董事会 负责最终考核结果的审核。 五、考核标准 （一）公司层面业绩考核 为保证本激励计划的顺利实施，公司根据《公司法》《证券法》《上市公司股 权激励管理办法》《上海证券交易所科创板股票上市规则》《科创板上市公司自律 监管指南第 4 号—股权激励信息披露》《公司章程》和《2024 年限制性股票激励 计划（草案修订稿）》等有关规定，结合实际情况，制定《2024 年限制性股票激 励计划考核管理办法（修订稿）》（以下简称"本办法"）。 一、考核目的 确保本激励计划的顺利实施，完善 ...

证券代码：688607 证券简称：康众医疗 公告编号：2025-015 江苏康众数字医疗科技股份有限公司 关于 2024 年限制性股票激励计划授予的部分限制性 股票作废失效的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏康众数字医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日分别召开第三届董事会第六次会议和第三届监事会第六次会议，审议通过 《关于 2024 年限制性股票激励计划授予的部分限制性股票作废失效的议案》，依 据《上市公司股权激励管理办法》《2024 年限制性股票激励计划（草案）》的有 关规定，公司董事会认为 2024 年限制性股票激励计划（以下简称"本激励计划"） 首次及预留授予第一个归属期未满足公司层面业绩考核，根据 2023 年年度股东 大会的授权，同意作废失效已授予的部分限制性股票 39.00 万股，涉及激励对象 18 名，有关情况如下： 一、本激励计划已履行的决策程序和信息披露情况 （一）2024 年 4 月 19 日，公司召开第二届董事会第十八次会议，审议通过 《关 ...

证券代码：688607 证券简称：康众医疗 公告编号：2025-011 江苏康众数字医疗科技股份有限公司 关于提请股东大会授权董事会办理以简易程序向 特定对象发行股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次授权事项概述 根据《上市公司证券发行注册管理办法》《上海证券交易所上市公司证券发 行上市审核规则》《上海证券交易所上市公司证券发行与承销业务实施细则》等 有关法律、法规、规范性文件和《公司章程》的规定，江苏康众数字医疗科技 股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第三届董事会第六 次会议，审议通过了《关于提请股东大会授权董事会办理以简易程序向特定对 象发行股票相关事宜的议案》，同意公司董事会提请股东大会授权董事会决定公 司向特定对象发行融资总额不超过人民币 3 亿元且不超过最近一年末净资产 20%的股票，授权期限自公司 2024 年年度股东大会审议通过之日起至公司 2025 年年度股东大会召开之日止。上述议案尚需提交公司年度股东大会审议通过。 二、本次授权具体内容 本 ...

一、主要会计数据和财务指标 | 名称 持有数量(万股) | | 占总股本比例 | 增减情况 | | --- | --- | --- | --- | | | | (%) | (万股) | | LIU,JIANQIANG | 1281.00 | 14.54 | 不变 | | 中新苏州工业园区创业投资有限公司 | 896.52 | 10.17 | 不变 | | 畅城有限公司 | 612.58 | 6.95 | -120.93 | | 高鹏 | 411.00 | 4.66 | 不变 | | 苏州康诚企业管理咨询服务有限公司 | 353.50 | 4.01 | 不变 | | 霍尔果斯君联承宇创业投资有限公司 | 245.53 | 2.79 | -37.03 | | 玄元私募基金投资管理(广东)有限公司-玄元科新233号私 募证券投资基金 | 199.81 | 2.27 | -0.30 | | 于亦春 | 166.00 | 1.88 | 新进 | | 宁波梅山保税港区同驰投资管理合伙企业(有限合伙) | 116.50 | 1.32 | 不变 | | 上海戊戌资产管理有限公司-戊戌价值15号私募证券投资 基金 | 81.0 ...

Financial Performance - The company's revenue for Q1 2025 was RMB 58,438,952.04, representing a 10.33% increase compared to RMB 52,969,765.80 in the same period last year[3] - The net profit attributable to shareholders was a loss of RMB 3,281,292.00, a decrease of 380.74% from a profit of RMB 1,168,820.49 in the previous year[3] - The basic earnings per share (EPS) was -0.04 RMB, down 479.11% from 0.01 RMB in the same period last year[3] - Total operating revenue for Q1 2025 was CNY 58,438,952.04, an increase of 10.4% compared to CNY 52,969,765.80 in Q1 2024[18] - The net profit for Q1 2025 was a loss of CNY 3,313,077.82, compared to a profit of CNY 1,190,756.45 in Q1 2024, indicating a significant decline in profitability[20] - The operating profit for Q1 2025 was a loss of CNY 1,951,083.79, down from a profit of CNY 2,038,345.06 in Q1 2024[19] Cash Flow - The net cash flow from operating activities was -RMB 34,634,632.56, significantly lower than -RMB 2,277,561.69 in the same period last year[3] - Cash flow from operating activities in Q1 2025 was CNY 69,670,228.34, a decrease from CNY 74,736,111.91 in Q1 2024[22] - The net cash flow from operating activities was -34,634,632.56, a significant decrease compared to -2,277,561.69 from the previous period, indicating a decline in operational efficiency[23] - Cash received from operating activities totaled 72,654,138.33, compared to 82,275,562.79, reflecting a decline in operational cash generation[23] - Cash paid for purchasing goods and services was 61,719,676.18, an increase from 47,638,703.03, indicating rising operational costs[23] Research and Development - Research and development (R&D) expenses totaled RMB 6,792,353.02, a decrease of 34.50% from RMB 10,369,812.18, with R&D expenses accounting for 11.62% of revenue, down 7.95 percentage points[4] - Research and development expenses for Q1 2025 were CNY 6,792,353.02, compared to CNY 10,369,812.18 in Q1 2024, showing a decrease of 34.8%[19] Assets and Liabilities - The company's total assets at the end of the reporting period were RMB 946,078,624.97, a decrease of 2.16% from RMB 966,947,228.28 at the end of the previous year[4] - Total liabilities decreased to CNY 86,718,504.63 from CNY 104,440,158.13, reflecting a reduction of approximately 17%[16] - The company's equity attributable to shareholders was CNY 859,642,422.00, slightly down from CNY 862,540,338.57[16] Shareholder Information - The company reported a total of 12,810,000 shares held by the largest shareholder, Liu Jianqiang, representing 14.54% of total shares[10] - The second-largest shareholder, China-Suzhou Industrial Park Venture Capital Co., Ltd., holds 8,965,203 shares, accounting for 10.17%[10] - The company has no significant changes in the participation of major shareholders in margin trading and securities lending activities[11] Future Outlook and Strategies - There are no significant new strategies or product developments mentioned in the conference call[12] - The company has not disclosed any future outlook or performance guidance in the provided documents[12] Investment Activities - Total cash inflow from investment activities was 517,663,809.70, down from 726,841,799.40, reflecting a reduction in investment returns[23] - The net cash flow from investment activities was 13,674,431.84, a decrease from 42,532,266.14, suggesting a slowdown in investment growth[23] - Cash outflow from financing activities totaled 2,585,236.86, compared to 12,430,996.97 in the previous period, indicating a reduction in financing costs[24] - The net cash flow from financing activities was -2,281,518.81, showing a significant decline from -12,430,996.97, which may impact future funding strategies[24] Inventory and Receivables - The company's accounts receivable slightly decreased to ¥102,898,838.48 from ¥108,079,615.10, indicating a reduction of approximately 4.0%[14] - Inventory increased to ¥99,887,672.71, up from ¥85,966,534.06, reflecting a growth of around 16.2%[14]

Financial Performance - The company's operating revenue for 2024 was CNY 298,100,384.74, an increase of 8.90% compared to the previous year[23]. - The net profit attributable to shareholders for 2024 was CNY 17,652,732.43, representing a growth of 14.54% year-over-year[26]. - The net profit after deducting non-recurring gains and losses reached CNY 5,944,151.22, a significant increase of 513.96% compared to the previous year[24]. - The net cash flow from operating activities was CNY 22,619,700.00, an increase of 5.32% from the previous year[24]. - Basic and diluted earnings per share for 2024 were CNY 0.20, up from CNY 0.17 in the previous year, marking a 14.72% increase[25]. - The weighted average return on equity was 2.05%, an increase of 0.24 percentage points year-over-year[27]. - The overall gross margin for the reporting period was 40.66%, an increase of 2.48 percentage points compared to the same period last year[45]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 0.61 per 10 shares to all shareholders, totaling RMB 5,330,869.61, which represents 30.20% of the net profit attributable to shareholders for the year 2024[5]. - The total share capital of the company is 88,129,027 shares, with 737,722 shares excluded from the profit distribution due to being held in a repurchase account[5]. - The company has not conducted any capital reserve transfers to increase share capital or issued bonus shares for the current year[5]. - The cash dividend represents 30.20% of the net profit attributable to the parent company's shareholders for the fiscal year 2024[200]. Research and Development - The company is focusing on the research and development of digital X-ray flat panel detectors and plans to expand into key components such as collimators and high-voltage generators[37]. - R&D expenses for the reporting period were approximately RMB 43.72 million, remaining stable compared to the previous year, with a focus on enhancing R&D efficiency[41]. - The company achieved the authorization of 7 invention patents, 8 utility model patents, and 6 design patents during the reporting period, reflecting its commitment to innovation[41]. - The company has developed a breakthrough DAEC technology that enables automatic control of exposure doses during imaging, enhancing the low-dose advantages of its iodide cesium technology[68]. - The company has made substantial progress in intelligent DR solutions, ensuring high resolution and dynamic range at low doses[89]. - The company is actively investing in the development of unconventional flat panel detectors, CMOS sensors, and advanced imaging technologies, with a long-term focus on integrating smart diagnostic systems[146]. Market Expansion and Sales Strategy - The company is actively expanding its sales channels and personnel in emerging markets such as South America, Asia-Pacific, and the Middle East[39]. - The company has established a global sales and service network covering over 30 countries, enhancing its competitive advantage in international markets[97]. - The company is focusing on optimizing its supply chain and cost control to improve production efficiency and capacity, while also enhancing local assembly and technical service capabilities overseas[145]. - The sales strategy is predominantly direct sales, targeting both domestic and international clients, with plans to expand sales centers in regions like the US, India, Japan, Italy, and South Korea[52]. Corporate Governance - The company has established a strong governance structure with independent directors contributing to oversight[168]. - The management team has been in place since 2017, ensuring stability and continuity in leadership[168]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 852.49 million RMB[172]. - The board of directors held a total of 10 meetings during the year, all conducted via communication methods[177]. Risks and Challenges - The company has outlined potential risks in its operations, which are detailed in the management discussion and analysis section[3]. - The company faced risks from intensified market competition and potential changes in macroeconomic conditions[103]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. Investment and Financial Management - The company plans to invest ¥50 million to establish a wholly-owned subsidiary and ¥30 million to participate in a venture capital fund[135]. - The total investment for the ongoing projects amounts to approximately ¥45.67 million, with a cumulative investment of ¥45.22 million[86]. - The company reported a 32.63% decrease in investment amount from ¥118.74 million to ¥80 million compared to the same period last year[138]. - The company has established a competitive salary mechanism, providing various insurances and housing funds for employees[188].